Efficacy of NS-718, a Novel Lipid Nanosphere-Encapsulated Amphotericin B, against Cryptococcus neoformans

AUTOR(ES)

Hossain, Mohammad Ashraf

FONTE

American Society for Microbiology

RESUMO

In vitro and in vivo efficacies of NS-718, a lipid nanosphere-encapsulated amphotericin B (AMPH-B), have been studied. Of the tested AMPH-B formulations, NS-718 had the lowest MIC for Cryptococcus neoformans. In a murine model, low-dose therapy (0.8 mg/kg of body weight) with NS-718 showed higher efficacy than that with AmBisome. High-dose therapy (2.0 mg/kg) with NS-718 was much more effective than those with Fungizone and AmBisome. In mice treated with a high dose of NS-718, only a few yeast cells had grown in lung by 7 days after inoculation. A pharmacokinetic study showed higher concentrations of AMPH-B in lung following administration of NS-718 than after administration of AmBisome. Our results indicated that NS-718, a new AMPH-B formulation, is a promising antifungal agent for treatment of pulmonary cryptococcosis and could be the most effective antifungal agent against C. neoformans infections.

Documentos Relacionados

• In Vitro and In Vivo Activities of NS-718, a New Lipid Nanosphere Incorporating Amphotericin B, against Aspergillus fumigatus
• Antifungal efficacy of amphotericin B encapsulated fibrin microsphere for treating Cryptococcus neoformans infection in Swiss albino mice
• Effect of ketoconazole and amphotericin B on encapsulated and non-encapsulated strains of Cryptococcus neoformans.
• Comparative Study of Trichothecin, Amphotericin B, and 5-Fluorocytosine Against Cryptococcus neoformans In Vitro and In Vivo
• Interactions between Triazoles and Amphotericin B against Cryptococcus neoformans